Immunohistochemical Evaluation of GATA-3 Expression in ER-Negative Breast Carcinomas
Haiyan Liu, Jianhui Shi, Jeffrey Prichard, Yun Gong, Fan Lin. Geisinger Medical Center, Danville, PA; University of Texas MD Anderson Cancer Center, Houston, TX
Background: Currently, estrogen receptor (ER), GCDFP-15 and mammaglobin are the most commonly used immunomarkers for identifying breast primary in tumors of unknown origin. The reported sensitivities for GCDFP-15 and mammaglobin are in the ranges of 35-55% and 65-70%, respectively. Our un-published data are even lower, 35% for GCDFP-15 and 50% for mammaglobin, which are similar to the reports by Bhargava et al and Lewis et al. Metastatic breast carcinomas (BCA) are likely high grade with ER-negative status. It is practical to find a sensitive and breast organ specific immunomarker. GATA-3 is a sensitive and specific marker for breast and urothelial carcinomas, as reported in our previous study (Liu H, et al. AJCP. 2012;138:57-64). However, the reactivity of GATA-3 in ER-negative breast carcinomas (BCA) has not been reported. In the current study, we conducted immunohistochemical analysis of GATA-3 expression in 96 cases of ER-negative BCA, including 49 tissue microarray (TMA) and 47 core needle biopsy (CNB) cases.
Design: Immunohistochemical evaluation of the expression of GATA-3 (Santa Cruz Biotech Inc, Cat. No. GATA3 [HG3-31]:sc-268) on 96 cases of ER-negative BCA using TMA sections (49 cases) and CNB specimens (47 cases) was conducted. The results were recorded.
Results: GATA-3 expression in 96 cases of ER-negative BCA is recorded in Table 1. Overall, 59% of TMA and 79% of CNB cases showed nuclear staining for GATA-3, with majority (73%) being strong (S) and diffuse (4 or 3+).
|Tumor Type||GATA-3 Expression, TMA||GATA-3 Expression, Core Biopsy|
|IDC, HG, Metaplastic||1||0||0||4||1||25|
|IDC, HG, Medullary Features||2||0||0||1||1||100|
|IDC, Apocrine Features||2||1||50||4||4||100|